Clinical Research Directory

Inclusion Criteria: 1. \> 18 years of age 2. Diagnosed with gastroenteropancreatic primary NET and has consented to undergo PRRT per the treating physician. Specifically: * Will consider other primaries on a case by case basis if dotatate scan (+) and meet all other criteria. * Metastatic or Locally Advanced AND Inoperable * Clear disease progression on Octreotide over less than 3 years (RECIST 1.1) * Presence of disease within 24 weeks as identified by PET/CT scans with Ga-68 DOTATATE reporting the Krenning score for low-grade NET and/or PET/CT scans with FDG for transformation to high-grade NET * Well differentiated on path - Ki67 \< 20% * Octreotide positive on pathology (if not documented, acceptable if PET/CT imaging shows lesions with Ga-68 DOTATATE uptakeLabs: * Cr. \<1.7 * Hgb \>8 * WBC \>2K * Plt \>75K * Bili \< 3x normal limit * No Octreotide within 30 days of administration. 3. Willing and able to comply with the protocol requirements 4. Able to comprehend and sign the Informed Consent Form in English. Exclusion Criteria: * Do not meet the Study Inclusion Criteria laid out in section 6.3